Recapitulating the clinical scenario of BRCA‐associated pancreatic cancer in pre‐clinical models

Medientyp: E-Artikel
Titel: Recapitulating the clinical scenario of BRCA‐associated pancreatic cancer in pre‐clinical models
Beteiligte: Golan, Talia; Stossel, Chani; Atias, Dikla; Buzhor, Ella; Halperin, Sharon; Cohen, Keren; Raitses‐Gurevich, Maria; Glick, Yulia; Raskin, Stephen; Yehuda, Daniel; Feldman, Anna; Schvimer, Michael; Friedman, Eitan; Karni, Rotem; Wilson, Julie M.; Denroche, Robert E.; Lungu, Ilinca; Bartlett, John M.S.; Mbabaali, Faridah; Gallinger, Steven; Berger, Raanan
Erschienen: Wiley, 2018
Erschienen in: International Journal of Cancer
Sprache: Englisch
DOI: 10.1002/ijc.31292
ISSN: 0020-7136; 1097-0215
Schlagwörter: Cancer Research ; Oncology
Entstehung:
Anmerkungen:
Beschreibung: <jats:p>Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal malignancies. <jats:italic>BRCA</jats:italic>‐associated PDAC comprises a clinically relevant subtype. A portion of these patients are highly susceptible to DNA damaging therapeutics, however, responses are heterogeneous and clinical resistance evolves. We have developed unique patient‐derived xenograft (PDX) models from metastatic lesions of germline <jats:italic>BRCA</jats:italic>‐mutated patients obtained at distinct time points; before treatment and at progression. Thus, closely mimicking clinical scenarios, to further investigate treatment naïve and resistant patients. DNA was isolated from six <jats:italic>BRCA</jats:italic>‐mutated PDXs and classified by whole‐genome sequencing to stable‐genome or homologous recombination deficient (HRD)‐genome. The sensitivity to DNA‐damaging agents was evaluated <jats:italic>in vivo</jats:italic> in three <jats:italic>BRCA</jats:italic>‐associated PDAC PDXs models: (1) HRD‐genome naïve to treatments; (2) stable‐genome naïve to treatment; (3) HRD‐genome resistant to treatment. Correlation between disease course at tissue acquisition and response to PARP inhibitor (PARPi)/platinum was demonstrated in PDXs <jats:italic>in vivo</jats:italic>. Only the HRD‐genome PDX, naïve to treatment, was sensitive to PARP inhibitor/cisplatin treatments. Our results demonstrate heterogeneous responses to DNA damaging agents/PARPi in <jats:italic>BRCA</jats:italic>‐associated PDX thus reflecting the wide clinical spectrum. An HRD‐genome PDX generated from a naïve to treatment biopsy was sensitive to platinum/PARPi whereas no benefit was observed in treating a HRD‐genome PDXs generated from a patient that had acquired resistance nor stable‐genome PDXs.</jats:p>
Zugangsstatus: Freier Zugang

Nur in Feld suchen:

Zuletzt gesuchte Begriffe: